|1.||Huang, T S: 3 articles (06/2001 - 02/2000)|
|2.||Tseng, Sheng-Hong: 2 articles (05/2006 - 11/2005)|
|3.||Chen, Yun: 2 articles (05/2006 - 11/2005)|
|4.||Chen, Jin-Cherng: 2 articles (05/2006 - 11/2005)|
|5.||Lee, C C: 2 articles (06/2001 - 02/2000)|
|6.||Shu, C H: 2 articles (03/2001 - 02/2000)|
|7.||Chen, L T: 2 articles (03/2001 - 02/2000)|
|8.||Lee, Kuo-Hsiung: 1 article (03/2010)|
|9.||Zhao, Hui: 1 article (11/2008)|
|10.||He, Feng-lian: 1 article (11/2008)|
02/01/2000 - "These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents."
02/28/2003 - "Therefore, our data showed that GL331 is a potent inhibitor of tumor-induced angiogenesis. "
02/28/2003 - "We have studied GL331's anti-cancer mechanisms by studying their effect on the tumor-induced angiogenesis. "
02/01/2000 - "In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents."
07/01/1999 - "GL331's overriding drug resistance and higher cancer cell-killing activity suggest its superiority in clinical cancer therapy."
05/01/2006 - "The glioma cells were treated with GL331 and the clonogenic assay was used to study its cytotoxicity effects. "
05/01/2006 - "The induction of GL331 radiosensitization was sequence-dependent, with stronger cytotoxic effects on the gliomas noted where radiation was delivered concomitantly with the beginning of GL331 treatment. "
05/01/2006 - "FACS analysis revealed that GL331 and radiation caused the glioma cells to accumulate in the G2/M-phase of the cell cycle and combination of these two treatments as the RT-GL331 protocol further increased the G2/M fraction of the glioma cells. "
05/01/2006 - "The clonogenic assay demonstrated that GL331 exerts cytotoxic effects on the glioma cells in a concentration- and time-dependent manner (p < 0.001). "
05/01/2006 - "The effects of combined GL331 and radiation treatment on human T98G glioma cells were also examined. "
|3.||Stomach Neoplasms (Stomach Cancer)
05/01/2002 - "A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. "
05/01/2002 - "Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients."
|4.||Prostatic Neoplasms (Prostate Cancer)
|1.||Type II DNA Topoisomerases (Topoisomerase II)
|2.||Etoposide (VP 16)
|5.||DNA (Deoxyribonucleic Acid)
|6.||trioctyl phosphine oxide (TOPO)
|7.||Topoisomerase II Inhibitors
|8.||bcl-2-Associated X Protein (bcl 2 Associated X Protein)